- Home
- MVO vs CGEN Comparison
MVO vs CGEN Comparison
Compare MVO & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVO
- CGEN
- Stock Information
- Founded
- MVO 2006
- CGEN 1993
- Country
- MVO United States
- CGEN Israel
- Employees
- MVO N/A
- CGEN N/A
- Industry
- MVO Oil & Gas Production
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MVO Energy
- CGEN Health Care
- Exchange
- MVO Nasdaq
- CGEN Nasdaq
- Market Cap
- MVO 110.7M
- CGEN 126.2M
- IPO Year
- MVO N/A
- CGEN 2000
- Fundamental
- Price
- MVO $9.16
- CGEN $1.45
- Analyst Decision
- MVO
- CGEN Strong Buy
- Analyst Count
- MVO 0
- CGEN 2
- Target Price
- MVO N/A
- CGEN $4.00
- AVG Volume (30 Days)
- MVO 55.1K
- CGEN 287.5K
- Earning Date
- MVO 01-01-0001
- CGEN 11-12-2024
- Dividend Yield
- MVO 17.46%
- CGEN N/A
- EPS Growth
- MVO N/A
- CGEN N/A
- EPS
- MVO 1.46
- CGEN 0.02
- Revenue
- MVO N/A
- CGEN $59,852,000.00
- Revenue This Year
- MVO N/A
- CGEN $18.69
- Revenue Next Year
- MVO N/A
- CGEN N/A
- P/E Ratio
- MVO $7.29
- CGEN $79.82
- Revenue Growth
- MVO N/A
- CGEN 698.03
- 52 Week Low
- MVO $8.85
- CGEN $0.62
- 52 Week High
- MVO $13.95
- CGEN $3.03
- Technical
- Relative Strength Index (RSI)
- MVO 53.66
- CGEN 35.64
- Support Level
- MVO $8.81
- CGEN $1.35
- Resistance Level
- MVO $9.23
- CGEN $1.85
- Average True Range (ATR)
- MVO 0.15
- CGEN 0.10
- MACD
- MVO 0.05
- CGEN -0.02
- Stochastic Oscillator
- MVO 85.71
- CGEN 20.00
About MVO MV Oil Trust Units of Beneficial Interests
MV Oil Trust is a statutory trust. Its underlying properties consist of MV Partners, LLC's (MV Partners) net interests in all of its oil and natural gas properties, which are located in the Mid-Continent region in the States of Kansas and Colorado. These oil and gas properties include producing oil and gas wells.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.